Fred Saad, MD

Conference Coverage

Darolutamide Demonstrates Efficacy and Safety for Metastatic Hormone-Sensitive Prostate Cancer

10/02/2024

Fred Saad, MD, discusses results from the phase 3 ARANOTE trial which assessed the efficacy and tolerability of adding darolutamide to androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Fred Saad, MD, discusses results...

10/02/2024

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

October 26 ⁠–⁠ October 27

October 29 ⁠–⁠ November 2

November 1 ⁠–⁠ November 2

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8

November 8 ⁠–⁠ November 10

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

See Full Calendar

Fred Saad, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products